Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: what and how do we value?

August 8, 2018 7:59am

Some sessions, I wonder ...

The immediate future seems to be always beyond investors as quickly it comes, it takes a day or two to disappear

Earnings: Adverum Biotechnologies (ADVM), Regenxbio (RGNX) Sangamo Therapeutics (SGMO), uniQure (QURE) and Verastem Onclogy (VSTM)

Pre-open indications: eleven (11)

Out and about: Pluristem Therapeutics Inc. (PSTI) Israel’s Ministry of Health has cleared patient recruitment in Israel for two ongoing pivotal P3 trials of PLX-PAD cell therapy, one for the treatment of Critical Limb Ischemia (CLI) and another for the treatment of muscle injury following hip fracture surgery. Both trials have been accepted to accelerated approval pathways and have received a total of $16.7 million in grants from the European Union’s Horizon 2020 Program.

Are the realities of “our” universe aligned with circumstance; RMi reports pre-open indications that shed light on share pricing events and today’s session values.

When is it wrong to be right so often? Your portfolio should be profiting from RMi’s analysis!

Want to know WHY? Subscribe!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.